Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca PLC    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Exclusive: AstraZeneca to miss second-quarter EU vaccine supply target by half - EU official

02/23/2021 | 09:25pm EST
FILE PHOTO: Coronavirus disease (COVID-19) vaccination in La Baule, France

BRUSSELS (Reuters) - AstraZeneca Plc has told the European Union it expects to deliver less than half the COVID-19 vaccines it was contracted to supply in the second quarter, an EU official told Reuters on Tuesday.

Contacted by Reuters, AstraZeneca did not deny what the official said, but a statement late in the day said the company was striving to increase productivity to deliver the promised 180 million doses.

The expected shortfall, which has not previously been reported, follows a big reduction in supplies in the first quarter and could hit the EU's ability to meet its target of vaccinating 70% of adults by summer.

The EU official, who is directly involved in talks with the Anglo-Swedish drugmaker, said the company had told the bloc during internal meetings that it "would deliver less than 90 million doses in the second quarter."

AstraZeneca's contract with the EU, which was leaked last week, showed the company had committed to delivering 180 million doses to the 27-nation bloc in the second quarter.

Asked about the EU official's comment, a spokesman for AstraZeneca initially said: "We are hopeful that we will be able to bring our deliveries closer in line with the advance purchase agreement."

Later in the day a spokesman in a new statement said the company's "most recent Q2 forecast for the delivery of its COVID-19 vaccine aims to deliver in line with its contract with the European Commission."

He added: "At this stage AstraZeneca is working to increase productivity in its EU supply chain and to continue to make use of its global capability in order to achieve delivery of 180 million doses to the EU in the second quarter."

A spokesman for the European Commission, which coordinates talks with vaccine manufacturers, said it could not comment on the discussions as they were confidential.

He said the EU should have more than enough shots to hit its vaccination targets if the expected and agreed deliveries from other suppliers are met, regardless of the situation with AstraZeneca.

The EU official, who spoke to Reuters on condition of anonymity, confirmed that AstraZeneca planned to deliver about 40 million doses in the first quarter, again less than half the 90 million shots it was supposed to supply.

AstraZeneca warned the EU in January that it would fall short of its first-quarter commitments due to production issues. It was also due to deliver 30 million doses in the last quarter of 2020 but did not supply any shots last year as its vaccine had yet to be approved by the EU.

All told, AstraZeneca's total supply to the EU could be about 130 million doses by the end of June, well below the 300 million it committed to deliver to the bloc by then.

The arrival of fewer AstraZeneca COVID-19 vaccines in the European Union in the second quarter has been factored into Irish forecasts that were updated on Tuesday, Prime Minister Micheál Martin said after Reuters reported the shortfall.

The EU has also faced delays in deliveries of the vaccine developed by Pfizer and BioNTech as well as Moderna's shot. So far they are the only vaccines approved for use by the EU's drug regulator.

AstraZeneca's vaccine was authorised in late January and some EU member states such as Hungary are also using COVID-19 shots developed in China and Russia.

OUTPUT BOOST DOWN THE LINE?

While drugmakers developed COVID-19 vaccines at breakneck speed, many have struggled with manufacturing delays due to complex production processes, limited facilities and bottlenecks in the supply of vaccine ingredients.

According to a German health ministry document dated Feb. 22, AstraZeneca is forecast to make up all of the shortfalls in deliveries by the end of September.

The document seen by Reuters shows Germany expects to receive 34 million doses in the third quarter, taking its total to 56 million shots, which is in line with its full share of the 300 million doses AstraZeneca is due to supply to the EU.

The German health ministry was not immediately available for a comment.

If AstraZeneca does ramp up its output in the third quarter, that could help the EU meet its vaccination target, though the EU official said the bloc's negotiators were wary because the company had not clarified where the extra doses would come from."Closing the gap in supplies in the third quarter might be unrealistic," the official said, adding that figures on deliveries had been changed by the company many times.

The EU contracts stipulate that AstraZeneca will commit to its "best reasonable efforts" to deliver by a set timetable.

We are continuously revising our delivery schedule and informing the European Commission on a weekly basis of our plans to bring more vaccines to Europe," the AstraZeneca spokesman said in his initial comment.

Under the EU contract leaked last week, AstraZeneca committed to producing vaccines for the bloc at two plants in the United Kingdom, one in Belgium and one in the Netherlands.

However, the company is not currently exporting vaccines made in the United Kingdom, in line with its separate contract with the British government, EU officials said.

AstraZeneca also has vaccine plants in other sites around the world and it has told the EU it could provide more doses from its global supply chain, including from India and the United States, an EU official told Reuters last week.

Earlier this month, AstraZeneca said it expected to make more than 200 million doses per month globally by April, double February's level, as it works to expand global capacity and productivity.

(Reporting by Francesco Guarascio @fraguarascio; Additional reporting by Andreas Rinke and Sabine Siebold; Editing by David Clarke and Howard Goller)

By Francesco Guarascio


© Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC 0.01% 6858 Delayed Quote.-6.38%
BIONTECH SE 1.10% 96.2 Delayed Quote.16.72%
MODERNA, INC. -0.08% 132.19 Delayed Quote.26.64%
PFIZER INC. 0.56% 34.39 Delayed Quote.-7.09%
US DOLLAR / RUSSIAN ROUBLE (USD/RUB) -0.59% 74.077 Delayed Quote.0.98%
All news about ASTRAZENECA PLC
08:53aTHE LATEST : Europe records 1M coronavirus cases last week
AQ
12:15aCHECK POINT SOFTWARE TECHNOLOGIES  : In Covid-19 Battle, Israeli Employers Offer..
DJ
03/05ASTRAZENECA  : Dentists, teachers, bus drivers want Oxford-AstraZeneca vaccine i..
AQ
03/05EXCLUSIVE : Oxford study indicates AstraZeneca effective against Brazil variant,..
RE
03/05ASTRAZENECA  : UK says vaccine shipment from India won't hurt poor nations
AQ
03/05MARKET CHATTER : AstraZeneca Vaccine Effective Against Brazil Variant
MT
03/05AstraZeneca effective against Brazil variant - source
RE
03/05What you need to know about Johnson & Johnson's approved single-dose vaccine
AQ
03/05Canada clears Johnson & Johnson vaccine, first to approve 4
AQ
03/05MARKET CHATTER : Preliminary Data Show AstraZeneca COVID-19 Jab Works Against Br..
MT
More news
Financials (USD)
Sales 2021 30 826 M - -
Net income 2021 4 711 M - -
Net Debt 2021 11 138 M - -
P/E ratio 2021 26,2x
Yield 2021 3,01%
Capitalization 125 B 124 B -
EV / Sales 2021 4,40x
EV / Sales 2022 3,81x
Nbr of Employees 76 100
Free-Float 95,8%
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 25
Average target price 129,18 $
Last Close Price 94,89 $
Spread / Highest target 65,6%
Spread / Average Target 36,1%
Spread / Lowest Target -0,04%
EPS Revisions
Managers and Directors
NameTitle
Pascal Soriot Chief Executive Officer & Executive Director
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA PLC-6.38%124 268
JOHNSON & JOHNSON-0.81%410 337
ROCHE HOLDING AG-1.63%274 753
PFIZER INC.-7.09%191 873
ABBVIE INC.-0.42%188 420
ELI LILLY AND COMPANY22.55%187 971